The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | 3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC
Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, discusses 3-year follow-up data from the Phase III CheckMate 649 trial (NCT02872116) of first-line nivolumab and chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC). Previous follow-ups have demonstrated the superiority of chemoimmunotherapy over chemotherapy alone, and a durable progression-free survival was observed in the 3-year follow-up with no additional toxicities reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CheckMate 629 is a very important trial in gastric cancer to change our practice. This is a three-month trial to compare chemotherapy plus nivolumab versus nivolumab plus ipilimumab versus standard chemotherapy. And here, we updated the three-year survival from chemotherapy plus nivolumab verses chemotherapy. In summary, these trials showed a very durable response, durable benefit in PFS and overall survival with nivolumab...
CheckMate 629 is a very important trial in gastric cancer to change our practice. This is a three-month trial to compare chemotherapy plus nivolumab versus nivolumab plus ipilimumab versus standard chemotherapy. And here, we updated the three-year survival from chemotherapy plus nivolumab verses chemotherapy. In summary, these trials showed a very durable response, durable benefit in PFS and overall survival with nivolumab. And this benefit to us especially in this team patient considered to be high CPS score, especially PD-L1 CPS 5 or higher cooperation. Risk of death was reduced by about 30% with a very durable, maintained survival benefit.
And there’s some talk since the information, but not very different from the previous publication. First publication, we announced it. And the second three or four was already published in nature. And now these three or four have confirmed they’re a durable survival benefit in PFS and overall survival with this combination. Research no especially conditional toxicity observation.
Read more...
